explore -WSS

explore

author：entertainment 2025-10-02 11:09:12 - browse：37881

gantenerumab Alzheimer's disease Roche — Sebastien Bozon/AFP via Getty Images

LONDON — Roche on Thursday said its recently acquired experimental obesity medication helped people lose a significant amount of weight in an early trial, sending its shares up in early trading.

The drug, a once-weekly injection known as CT-388, resulted in an average placebo-adjusted weight loss of 18.8% after 24 weeks, the company said. The study was a Phase 1 trial, though it was placebo-controlled.

The reaction to such an early result — Roche shares were up roughly 4% early Thursday — is a signal both of the stakes of the obesity medication race and the keen interest investors have in the field.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： The tragedy of Johnson & Johnson’s Covid vaccine

knowledge

WSS

My yearlong odyssey to get my son’s ADHD medication covered

Elizabeth Holmes banned from government health programs

Stanford updates investigation of president’s past research

Stanford updates investigation of president’s past research

Think you might have Covid

Copay coupons to count toward deductibles, after Biden court move

entertainment

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

knowledge

What does generative AI mean for health care? We asked experts

Why some people catch Covid but never get sick

Peter Hotez and the public health issue of online harassment

Couple fighting to bring baby home from Mexico are finally reunited

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Suspected Gilgo Beach killer appeared 'traumatized' after arrest: Defense attorney

United colonoscopy coverage change 'may cost lives,' doctors say

Plane’s emergency slide plummets from sky, hits Chicago home

After affirmative action ruling, medical educators look to 'holistic review'

The tragedy of Johnson & Johnson’s Covid vaccine

focus

Humana cuts profit projections as Medicare Advantage costs soar

Readout Newsletter: Merck, J&J, and long Covid

Why some people catch Covid but never get sick

Prior authorization will have to move faster under new Biden rule

Medicare Advantage today, explained in one chart

Research misconduct: Proposed new rules face resistance

focus

knowledge

explore

hotspot